Skip to main content
. 2025 Aug 22;11(34):eadv6937. doi: 10.1126/sciadv.adv6937

Fig. 9. Dysregulation of the AKR1B10–c-Myc–ITGB8 axis drives CRC progression.

Fig. 9.

(A and B) Representative H&E and IHC images (A) and quantification (B) of AKR1B10, ITGB8, and c-Myc staining in paired primary CRC tissues and liver metastatic lesions from 20 patients. (C and D) Representative IHC images (C) and histoscore (D) of AKR1B10, ITGB8, and c-Myc staining in primary tumors and liver sections from the HCT116 orthotopic implantation mouse model (n = 6). (E) Correlation analysis of IHC scores between AKR1B10 and ITGB8 or c-Myc in CRC TMAs. (F and G) Kaplan-Meier survival curves of patients with CRC stratified by high or low c-Myc/ITGB8 expression levels (F) and AKR1B10/ITGB8 or AKR1B10/c-Myc expression levels (G) from CRC TMAs. (H) Schematic diagram illustrating how down-regulated AKR1B10 accelerates CRC metastasis. Ub, ubiquitin. Data are presented as mean ± SD, with paired (B) or unpaired (D) Student’s t test or log-rank test (G).